Gene Therapy Trials and Tribulations
This article was originally published in Start Up
Executive SummaryThe increased scrutiny of gene therapy by the National Institutes of Health and the Food and Drug Administration hasn't, to date, affected companies' clinical trials or long-term strategies, say executives of companies working in the field. This is partly because the NIH and FDA have yet to announce what new requirements, if any, companies must meet. Another reason is that few companies are working with adenoviral vectors--the focus of much attention following the death in September of an 18-year-old patient while in a gene therapy experiment.
You may also be interested in...
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?